Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02349633 · ClinicalTrials.gov registry record · Phase 1
Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT02349633 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 65 participants.
The verdict
NCT02349633, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
This is a Phase 1/2 study of PF-06747775 as a single agent and in combination with other cancer treatments in patients with advanced EGFRm NSCLC. The overall clinical study consists of a Phase 1 single agent dose-escalation and expansion part to determine the RP2D of PF-06747775 single agent in patients with previously-treated EGFRm NSCLC followed by sequential evaluations of PF-06747775 at the RP2D in 3 different clinical scenarios as detailed below: * Cohort 1: Phase 2 evaluation of PF-06747775 as a single agent in previously untreated patients with advanced EGFRm NSCLC, * Cohort 2: Phase 1b single arm evaluation of PF-06747775 in combination with palbociclib (Cohort 2A) followed by Phase 2 randomized evaluation of PF 06747775 in combination with palbociclib vs PF-06747775 single agent (Cohort 2B) in previously-treated patients with EGFRm NSCLC with a secondary T790M mutation (del 19 and T790M or L858R and T790M), and * Cohort 3: Phase 1b evaluation of PF-06747775 in combination with avelumab in previously-treated patients with EGFRm NSCLC with a secondary T790M mutation (del 19 and T790M or L858R and T790M).
Interventions
- DRUG Palbociclib
- DRUG Avelumab
- DRUG PF-06747775
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2015-05-14 |
| Est. Completion | 2020-05-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02349633
The ClinicalTrials.gov registry entry for NCT02349633 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Palbociclib is the first listed.
NCT02349633 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02349633 about?
NCT02349633 is a clinical study titled "Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)". This is a Phase 1/2 study of PF-06747775 as a single agent and in combination with other cancer treatments in patients with advanced EGFRm NSCLC. The overall clinical study consists of a Phase 1 single agent dose-escalation and expansion part to determine the RP2D of PF-06747775 single agent in pati...
What is the current status of trial NCT02349633?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2015-05-14. Estimated completion is 2020-05-28.
What interventions are being tested in trial NCT02349633?
The interventions under investigation include: Palbociclib (DRUG), Avelumab (DRUG), PF-06747775 (DRUG).
Who is sponsoring clinical trial NCT02349633?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.